News & Events
In the news
Clean Mails – December 2022
Naobios, your partner in the production of Human Viral Challenge Agents
Naobios today announces its investment in the manufacturing of Human Viral Challenge Agents.
Clean Mails – September 2022
Naobios x GenSensor: a partnership for bioprocess optimization
Naobios and GenSensor, two renowned companies of the biopharma sector, have announced a partnership to further advance bioprocess optimization for clinical lots of viral vaccines and vectors. It will allow for enhanced bioprocesses and optimized scale-up.
Press Release
Naobios delivers FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the United States.
Clean Mails – May 2022
GMP biomanufacturing in a BSL-3 suite
A GMP biomanufacturing expert, Naobios has worked with numerous viruses requiring specific biocontainment procedures. Our state-of-the-art BSL-3 suite welcome hazardous microbes used for the generation of virus-based therapeutic products.
New webinar
How can customized solutions speed up successful GMP manufacturing?
The next edition of our webinar series will be centred on customised solutions when designing GMP processes to manufacture biologics and will take place on June, 23rd.
Discover our team:
Ysaline Roland, Production manager at Naobios
Our newest series of articles promote the people that make up our company and its human-centric values and objectives. Our latest profile is dedicated to Ysaline Roland, Production Manager at Naobios.
Collaboration
Naobios signs Service Agreement with Nobelpharma
Naobios will rely on its 15 years of expertise in process development and GMP manufacturing to support Nobelpharma develop its product. Naobios collaborated last year with the Japan-based company on preliminary studies.
Clean Mails – Revue scientifique trimestrielle
BSL3 GMP manufacturing suite – Naobios
Our team at Naobios has qualified a highly-secured BSL3 GMP manufacturing suite in our multipurpose facility to accommodate challenging GMP production projects involving viral vaccines, viral vectors and oncolytic viruses.